Who
Gene G. Kinney
President and CEO
Company insider
Files Form 4 as: President and CEO, Prothena Corporation.
In numbers
- Trades disclosed
- 108
- Buys
- 1
- Sells
- 17
- Bought
- $49K
- Sold
- $12.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Jan 2013
- Last trade
- 28 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | —84,000 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code D | $719K84,000 at $8.56 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —84,000 at $0.00 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —84,000 at $0.00 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | —84,000 | filing |
| 28 Jul 2026filed 30 Jul 2026 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code D | $719K84,000 at $8.56 | filing |
| 3 Mar 2026filed 5 Mar 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —520,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —520,000 at $0.00 | filing |
| 28 Jul 2025filed 30 Jul 2025 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 5 Mar 2025filed 7 Mar 2025 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —307,000 at $0.00 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,000 at $0.00 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | $1.3M45,000 at $29.81 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $742K10,202 at $72.70 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $1.5M19,864 at $73.60 | filing |
| 17 May 2023filed 17 May 2023 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $1.1M14,934 at $74.49 | filing |
| 2 Mar 2023filed 3 Mar 2023 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 28 Sep 2022filed 30 Sep 2022 | PRTA Prothena Corporationoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,412 at $0.00 | filing |
| 28 Sep 2022filed 30 Sep 2022 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Code M | $105K16,412 at $6.41 | filing |
| 28 Sep 2022filed 30 Sep 2022 | PRTA Prothena CorporationBiotechnology | SEC FORM 4 Sold | $50K1,045 at $48.09 | filing |
News
Prothena Corporation plc (PRTA) – What Are Analysts Saying About This Stock?PRTA · dailypolitical.com · 20 Oct 2026Prothena (NASDAQ:PRTA) Major Shareholder William Scully Buys 100,000 Shares of Company StockPRTA · dailypolitical.com · 15 Oct 2026Prothena (NASDAQ:PRTA) vs. Kyntra Bio (NASDAQ:KYNB) Financial ReviewPRTA · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Gene G. Kinney; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.